Sort by
Keyphrases
Cost-effectiveness
58%
Cost-effectiveness Analysis
56%
Quality-adjusted Life Years
51%
Type 2 Diabetes Mellitus (T2DM)
38%
Texas
36%
Incremental Cost-effectiveness Ratio
34%
United States
28%
Placebo
23%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
23%
Olaparib
23%
Ribociclib
23%
Willingness-to-pay Threshold
16%
Drosophilidae
16%
Chemotherapy
16%
Commercial Insurance
16%
Payer Perspective
16%
Health Disparities
15%
Niraparib
15%
Systemic Sclerosis
15%
Drosophila Larvae
15%
Economic Burden
15%
Conjoint Analysis
15%
Diabetes-related Costs
15%
Pembrolizumab
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
15%
Atezolizumab
15%
Endocrine Therapy
15%
Therapeutic Potential
15%
Postmenopausal Women
15%
Maintenance Treatment
15%
Cost-utility Analysis
15%
COVID-19
15%
Patient Preference
15%
Platinum-resistant Ovarian Cancer
15%
Disease-modifying Therapy
14%
Abiraterone
14%
Probabilistic Sensitivity Analysis
13%
Opioids
12%
Patients with Diabetes
12%
Progression-free Survival
12%
Rurality
10%
Treatment Decisions
10%
Clinical Outcomes
10%
Prostate Cancer Patients
10%
Hemoglobin A1c (HbA1c)
10%
Insurer
10%
Maintenance Therapy
10%
Healthcare Resource Utilization
10%
Pain Management
9%
High Cost
9%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
82%
Quality Adjusted Life Year
38%
Breast Cancer
24%
Placebo
23%
Ribociclib
23%
Prostate Cancer
23%
Maintenance Therapy
23%
Olaparib
23%
COVID-19
23%
Diabetes
21%
Maturity Onset Diabetes of the Young
16%
Health Disparity
16%
Clinical Trial
15%
Malignant Neoplasm
15%
Hormone Therapy
15%
Niraparib
15%
Public Health
15%
Recurrent Ovarian Cancer
15%
Castration Resistant Prostate Cancer
15%
Real-World Evidence
15%
Real-World Data
14%
Progression Free Survival
13%
Mortality Rate
10%
Logistic Regression Analysis
10%
Arm
10%
Cross Sectional Study
10%
Analgesia
9%
Global Disease Burden
9%
Hormone Receptor
9%
Health Care Access
9%
Disease Burden
8%
Preference
8%
Epidermal Growth Factor Receptor 2
8%
Gamma Urogastrone
8%
Diseases
8%
Health Status
7%
Premenopause
7%
Dexamethasone
7%
Gene Mutation
7%
Multiple Myeloma
7%
Chronic Pain
7%
Avelumab
7%
Metastatic Breast Cancer
7%
First-Line Chemotherapy
7%
Patient Health Questionnaire 9
7%
Climacterium
7%
Daratumumab
7%
Urinary System
7%
Lenalidomide
7%